ICON Public (NASDAQ:ICLR – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $15.00-$15.20 for the period, compared to the consensus estimate of $15.07. The company issued revenue guidance of $8.45-$8.55 billion, compared to the consensus revenue estimate of $8.64 billion.
Analysts Set New Price Targets
Several brokerages have issued reports on ICLR. Robert W. Baird boosted their price target on shares of ICON Public from $367.00 to $376.00 and gave the company an outperform rating in a report on Monday, July 8th. Mizuho reaffirmed a buy rating and issued a $346.00 target price on shares of ICON Public in a report on Thursday, April 4th. The Goldman Sachs Group assumed coverage on shares of ICON Public in a report on Thursday, June 6th. They issued a buy rating and a $370.00 target price on the stock. TD Cowen upped their target price on shares of ICON Public from $349.00 to $373.00 and gave the stock a buy rating in a report on Friday, May 31st. Finally, Truist Financial upped their target price on shares of ICON Public from $367.00 to $383.00 and gave the stock a buy rating in a report on Friday. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $352.56.
Read Our Latest Stock Analysis on ICLR
ICON Public Trading Up 2.5 %
ICON Public (NASDAQ:ICLR – Get Free Report) last announced its earnings results on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, topping the consensus estimate of $3.68 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.14 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.18%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $2.96 EPS. On average, research analysts predict that ICON Public will post 14.54 EPS for the current fiscal year.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading
- Five stocks we like better than ICON Public
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Are Penny Stocks a Good Fit for Your Portfolio?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What is a buyback in stocks? A comprehensive guide for investors
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.